Doug Manion of Bristol-Myers Squibb presented at the Bank of America Merrill Lynch Health Care Conference on May 17, 2012. He discussed Bristol-Myers Squibb's hepatitis C virus drug portfolio, including their NS5A inhibitor daclatasvir and protease inhibitor asunaprevir, which are in Phase III trials. He also discussed their nucleoside polymerase inhibitor -189, which they acquired from Inhibitex, and its potential role in their HCV regimen. Bristol-Myers Squibb aims to achieve higher cure rates for HCV through improved efficacy, safety, and shorter treatment durations compared to current standards of care.